DK3193611T3 - Mk2-inhibitorer og anvendelser deraf - Google Patents
Mk2-inhibitorer og anvendelser deraf Download PDFInfo
- Publication number
- DK3193611T3 DK3193611T3 DK15842903.5T DK15842903T DK3193611T3 DK 3193611 T3 DK3193611 T3 DK 3193611T3 DK 15842903 T DK15842903 T DK 15842903T DK 3193611 T3 DK3193611 T3 DK 3193611T3
- Authority
- DK
- Denmark
- Prior art keywords
- inhibitors
- Prior art date
Links
- 229940124789 MK2 inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051788P | 2014-09-17 | 2014-09-17 | |
| US201562199927P | 2015-07-31 | 2015-07-31 | |
| PCT/US2015/050495 WO2016044463A2 (en) | 2014-09-17 | 2015-09-16 | Mk2 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3193611T3 true DK3193611T3 (da) | 2021-05-10 |
Family
ID=55454109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15842903.5T DK3193611T3 (da) | 2014-09-17 | 2015-09-16 | Mk2-inhibitorer og anvendelser deraf |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US9458175B2 (enExample) |
| EP (2) | EP3193611B1 (enExample) |
| JP (3) | JP6556225B2 (enExample) |
| KR (1) | KR102457848B1 (enExample) |
| CN (1) | CN106998692B (enExample) |
| AU (1) | AU2015317741B2 (enExample) |
| BR (1) | BR112017005266B1 (enExample) |
| CA (1) | CA2961607C (enExample) |
| CL (1) | CL2017000576A1 (enExample) |
| CO (1) | CO2017003279A2 (enExample) |
| CY (1) | CY1124215T1 (enExample) |
| DK (1) | DK3193611T3 (enExample) |
| EA (1) | EA037299B1 (enExample) |
| EC (1) | ECSP17023281A (enExample) |
| ES (1) | ES2874561T3 (enExample) |
| HR (1) | HRP20210529T1 (enExample) |
| HU (1) | HUE054347T2 (enExample) |
| IL (1) | IL251051B (enExample) |
| LT (1) | LT3193611T (enExample) |
| MA (1) | MA40534B1 (enExample) |
| MX (2) | MX373341B (enExample) |
| PL (1) | PL3193611T3 (enExample) |
| PT (1) | PT3193611T (enExample) |
| RS (1) | RS62017B1 (enExample) |
| SA (1) | SA517381115B1 (enExample) |
| SG (2) | SG10201902326XA (enExample) |
| SI (1) | SI3193611T1 (enExample) |
| SM (1) | SMT202100311T1 (enExample) |
| TW (1) | TWI744217B (enExample) |
| WO (1) | WO2016044463A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150133172A (ko) | 2013-03-15 | 2015-11-27 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Mk2 억제제 및 이의 용도 |
| SG10201902326XA (en) | 2014-09-17 | 2019-04-29 | Celgene Car Llc | Mk2 inhibitors and uses thereof |
| CN106632077B (zh) * | 2016-10-10 | 2019-01-22 | 上海再启生物技术有限公司 | 一种2-氨基-4-溴嘧啶的制备方法 |
| JP2020511468A (ja) * | 2017-03-16 | 2020-04-16 | セルジーン シーエーアール エルエルシー | Ｍｋ２阻害剤の重水素化アナログおよびその使用 |
| US11124525B2 (en) | 2017-03-16 | 2021-09-21 | Celgene Car Llc | Heteroaryl compounds useful as MK2 inhibitors |
| CA3054826A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Mk2 inhibitors, synthesis thereof, and intermediates thereto |
| CN110678178B (zh) * | 2017-03-16 | 2023-10-03 | 百时美施贵宝公司 | Mk2抑制剂的形式和组合物 |
| JP2020514361A (ja) * | 2017-03-16 | 2020-05-21 | セルジーン シーエーアール エルエルシー | ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用 |
| CN107058259A (zh) * | 2017-05-18 | 2017-08-18 | 南京中医药大学 | 分子标志物mk2基因及其应用 |
| AU2019351912B2 (en) * | 2018-10-02 | 2025-07-31 | Disc Medicine, Inc. | Matriptase 2 inhibitors and uses thereof |
| WO2020236636A1 (en) * | 2019-05-17 | 2020-11-26 | Celgene Car Llc | Methods of treating a mk2-mediated disorder |
| WO2021163633A1 (en) * | 2020-02-14 | 2021-08-19 | Salk Institute For Biological Studies | Mono and combination therapies with ulk1/2 inhibitors |
| EP4114411A4 (en) * | 2020-03-02 | 2024-04-24 | Washington University | Compositions and methods for the treatment of pancreatic cancer |
| KR20230044446A (ko) * | 2020-07-24 | 2023-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | 급성 호흡기 장애의 치료 방법 |
| CA3201774A1 (en) * | 2020-11-12 | 2022-05-19 | Akttyva Therapeutics, Inc. | Mk2 activating compounds for use in treating vascular leak and endothelial barrier disorders |
| EP4284805A1 (en) * | 2021-02-01 | 2023-12-06 | Celgene Corporation | Mk2 inhibitors, the synthesis thereof, and intermediates thereto |
| EP4079855A1 (en) * | 2021-04-20 | 2022-10-26 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Compound and method for the prophylaxis and treatment of leukemia |
| CN117940433A (zh) * | 2021-08-27 | 2024-04-26 | 瑞石生物医药有限公司 | 喹啉并呋喃衍生物及其用途 |
| AU2023207395A1 (en) | 2022-01-14 | 2024-07-11 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof |
| WO2024044731A1 (en) * | 2022-08-26 | 2024-02-29 | Matchpoint Therapeutics Inc. | Diazepino-thieno-quinoxaline compounds and their use in therapy |
| EP4608401A2 (en) * | 2022-10-27 | 2025-09-03 | Bristol-Myers Squibb Company | Mk2 inhibitors and uses thereof |
| EP4661875A1 (en) * | 2023-02-07 | 2025-12-17 | Celgene Corporation | Compounds and compositions useful as degraders of mk2 kinase |
| WO2024229401A2 (en) * | 2023-05-04 | 2024-11-07 | Matchpoint Therapeutics Inc. | Diazepino-thieno-quinoxaline compounds and their use in therapy |
| WO2025002076A1 (zh) * | 2023-06-26 | 2025-01-02 | 深圳信立泰药业股份有限公司 | 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5015778A (en) | 1989-12-18 | 1991-05-14 | The Dow Chemical Company | Catalytic method to produce hydroxy substituted arylophenones |
| JP3696884B2 (ja) | 1994-03-25 | 2005-09-21 | アイソテクニカ、インコーポレーテッド | ジュウテリウム化による薬物の効能の増強 |
| US5441946A (en) | 1994-04-14 | 1995-08-15 | Rhone-Poulenc-Rorer Pharmaceuticals, Inc. | Phosphonate derivatives of lipophilic amines |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| US6861440B2 (en) * | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| AU2003301226A1 (en) | 2002-12-20 | 2004-07-22 | Pharmacia Corp | Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2 |
| JP5010917B2 (ja) | 2003-08-29 | 2012-08-29 | エグゼリクシス， インコーポレイテッド | ｃ−Ｋｉｔ調節因子および使用方法 |
| WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| MY158077A (en) | 2005-02-04 | 2016-08-30 | Senomyx Inc | Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers tastants and taste enhancers for comestible compositions |
| EP1849781A1 (en) | 2006-04-28 | 2007-10-31 | Laboratorios del Dr. Esteve S.A. | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments |
| EP2223925A1 (en) | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| CN101687869A (zh) | 2007-07-16 | 2010-03-31 | 诺瓦提斯公司 | 作为mk2抑制剂的四环内酰胺衍生物 |
| AU2008317057B8 (en) | 2007-10-22 | 2014-02-13 | Merck Sharp & Dohme Corp. | Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| EP2361248B1 (en) | 2008-06-27 | 2018-09-19 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| US20110269744A1 (en) * | 2010-03-12 | 2011-11-03 | Astellas Pharma Inc. | Benzazepine Compound |
| WO2011153553A2 (en) * | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| EP2508511A1 (en) * | 2011-04-07 | 2012-10-10 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| EP2511273B8 (en) * | 2011-04-15 | 2019-06-26 | Hivih | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| CN104136576B (zh) | 2012-02-22 | 2020-10-16 | 默克专利股份有限公司 | 液晶介质 |
| WO2013146963A1 (ja) * | 2012-03-28 | 2013-10-03 | 武田薬品工業株式会社 | 複素環化合物 |
| TW201406758A (zh) * | 2012-06-28 | 2014-02-16 | Daiichi Sankyo Co Ltd | 三環性化合物 |
| EP2872144A4 (en) * | 2012-07-11 | 2015-12-02 | Nimbus Iris Inc | IRAQ INHIBITOR AND USES THEREOF |
| MA38030B1 (fr) * | 2012-09-24 | 2019-11-29 | Claremont Speede | Accès à des données contrôlé par un expéditeur mobile, et procédé et système de suppression de données |
| WO2014050779A1 (ja) * | 2012-09-25 | 2014-04-03 | 第一三共株式会社 | Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| KR20150133172A (ko) * | 2013-03-15 | 2015-11-27 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Mk2 억제제 및 이의 용도 |
| WO2015050957A2 (en) | 2013-10-02 | 2015-04-09 | Treatments For Systemic Lupus Erythematosus | Treatments for systemic lupus erythematosus |
| WO2016032882A1 (en) | 2014-08-25 | 2016-03-03 | Stc.Unm | Inhibition of mk2 in the treatment of cancer |
| SG10201902326XA (en) | 2014-09-17 | 2019-04-29 | Celgene Car Llc | Mk2 inhibitors and uses thereof |
| MX2017008994A (es) | 2015-01-08 | 2018-09-18 | Moerae Matrix Inc | Formulacion de peptidos inhibidores mk2. |
| CA3054826A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Mk2 inhibitors, synthesis thereof, and intermediates thereto |
| JP2020511468A (ja) | 2017-03-16 | 2020-04-16 | セルジーン シーエーアール エルエルシー | Ｍｋ２阻害剤の重水素化アナログおよびその使用 |
| US11124525B2 (en) | 2017-03-16 | 2021-09-21 | Celgene Car Llc | Heteroaryl compounds useful as MK2 inhibitors |
| CN110678178B (zh) | 2017-03-16 | 2023-10-03 | 百时美施贵宝公司 | Mk2抑制剂的形式和组合物 |
| JP2020514361A (ja) | 2017-03-16 | 2020-05-21 | セルジーン シーエーアール エルエルシー | ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用 |
| WO2020236636A1 (en) | 2019-05-17 | 2020-11-26 | Celgene Car Llc | Methods of treating a mk2-mediated disorder |
| KR20230044446A (ko) | 2020-07-24 | 2023-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | 급성 호흡기 장애의 치료 방법 |
-
2015
- 2015-09-16 SG SG10201902326XA patent/SG10201902326XA/en unknown
- 2015-09-16 CN CN201580058026.4A patent/CN106998692B/zh active Active
- 2015-09-16 SI SI201531617T patent/SI3193611T1/sl unknown
- 2015-09-16 WO PCT/US2015/050495 patent/WO2016044463A2/en not_active Ceased
- 2015-09-16 EP EP15842903.5A patent/EP3193611B1/en active Active
- 2015-09-16 JP JP2017515845A patent/JP6556225B2/ja active Active
- 2015-09-16 HR HRP20210529TT patent/HRP20210529T1/hr unknown
- 2015-09-16 US US14/856,311 patent/US9458175B2/en active Active
- 2015-09-16 SM SM20210311T patent/SMT202100311T1/it unknown
- 2015-09-16 SG SG11201701861RA patent/SG11201701861RA/en unknown
- 2015-09-16 PT PT158429035T patent/PT3193611T/pt unknown
- 2015-09-16 EP EP21164056.0A patent/EP3912981A1/en active Pending
- 2015-09-16 MX MX2017003359A patent/MX373341B/es active IP Right Grant
- 2015-09-16 AU AU2015317741A patent/AU2015317741B2/en active Active
- 2015-09-16 EA EA201790380A patent/EA037299B1/ru not_active IP Right Cessation
- 2015-09-16 LT LTEP15842903.5T patent/LT3193611T/lt unknown
- 2015-09-16 CA CA2961607A patent/CA2961607C/en active Active
- 2015-09-16 RS RS20210725A patent/RS62017B1/sr unknown
- 2015-09-16 DK DK15842903.5T patent/DK3193611T3/da active
- 2015-09-16 ES ES15842903T patent/ES2874561T3/es active Active
- 2015-09-16 MA MA40534A patent/MA40534B1/fr unknown
- 2015-09-16 KR KR1020177010439A patent/KR102457848B1/ko active Active
- 2015-09-16 HU HUE15842903A patent/HUE054347T2/hu unknown
- 2015-09-16 PL PL15842903T patent/PL3193611T3/pl unknown
- 2015-09-16 TW TW104130645A patent/TWI744217B/zh active
- 2015-09-16 BR BR112017005266-0A patent/BR112017005266B1/pt active IP Right Grant
-
2016
- 2016-09-29 US US15/280,157 patent/US9790235B2/en active Active
-
2017
- 2017-03-09 CL CL2017000576A patent/CL2017000576A1/es unknown
- 2017-03-09 IL IL25105117A patent/IL251051B/en active IP Right Grant
- 2017-03-14 MX MX2020005213A patent/MX2020005213A/es unknown
- 2017-03-16 SA SA517381115A patent/SA517381115B1/ar unknown
- 2017-04-04 CO CONC2017/0003279A patent/CO2017003279A2/es unknown
- 2017-04-13 EC ECIEPI201723281A patent/ECSP17023281A/es unknown
- 2017-10-13 US US15/782,995 patent/US10253040B1/en active Active
-
2019
- 2019-04-04 US US16/375,317 patent/US10577380B2/en active Active
- 2019-07-09 JP JP2019127476A patent/JP2019194236A/ja active Pending
-
2020
- 2020-02-27 US US16/802,654 patent/US11584757B2/en active Active
-
2021
- 2021-06-09 CY CY20211100504T patent/CY1124215T1/el unknown
-
2022
- 2022-03-16 JP JP2022041396A patent/JP7375072B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3193611T3 (da) | Mk2-inhibitorer og anvendelser deraf | |
| IL280863A (en) | Autotaxin inhibitors and uses thereof | |
| DK3215147T3 (da) | Neurodæmpende norketamin-forbindelser og fremgangsmåder | |
| DK3521289T3 (da) | Mnk-inhibitorer og fremgangsmåder forbundet dermed | |
| DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
| DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
| DK3205650T3 (da) | Egfr-hæmmer og fremstilling og anvendelse deraf | |
| DK3888658T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
| HUE042335T2 (hu) | ROR-gamma dihidropirrolopiridin inhibitorai | |
| DK3201351T3 (da) | Kaloriefrie sødestoffer og fremgangsmåder til syntetisering | |
| DK3212189T3 (da) | Substituerede chromaner og fremgangsmåde til anvendelse deraf | |
| DK3229838T3 (da) | Anti-C10orf54-antistoffer og anvendelser deraf | |
| DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
| DK3015526T3 (da) | Hydrofluorolefinbaseret sammensætning og anvendelse deraf | |
| DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
| DK3209773T3 (da) | Prolintolerante tripeptidylpeptidaser og anvendelser deraf | |
| DK3186242T3 (da) | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere | |
| DK3474883T3 (da) | Komplementinhibitorer og anvendelser deraf | |
| DK3321279T3 (da) | Exenatidmodificeringsmiddel og anvendelse deraf | |
| DK3142659T3 (da) | Hiv-1 proteasehæmmere og anvendelser deraf | |
| DK3337506T3 (da) | Kombinationer og anvendelser deraf | |
| DK3280405T3 (da) | Inhibitorer og anvendelser deraf | |
| DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf | |
| DK3152305T3 (da) | Prolinspecifik endoprotease og anvendelse deraf | |
| DK3240821T3 (da) | Lavdosis gashydrathæmmersammensætning og tilhørende fremgangsmåde |